About
Products
Knolens
KnolScapes
Knolens
Knolens SLR
Knolens
KnolQuest
Knolens
Edge
Knolens
DataNexus
Platform
Solutions
KnolSights
Experience Knolens
Ziftomenib Shows Promise in Treating Relapsed/Refractory NPM1-Mutant AML
Kura Oncology and Kyowa Kirin announced positive pivotal data for ziftomenib, an oral menin inhibitor, in patients with relapsed/refractory (R/R) NPM1...
Copyright © 2025. All rights reserved
About
Terms of Service
Privacy Policy
Home/
KnloSights/
Clinical Trial Updates/
Ziftomenib Shows Promise in Treating Relapsed/Refractory NPM1-Mutant AML